Keros Therapeutics, Inc. (KROS)
NasdaqGM · USD · Healthcare · Biotechnology
$11.34 (+0.09%) as of
Key statistics
- Market cap
- 224.84M
- Forward P/E
- -1.71
- EPS (TTM)
- -3.23
- Dividend yield
- 0.00%
- 52-week range
- 9.69 – 22.55
- Beta
- 1.12
- Revenue (TTM)
- 15.01M
- Profit margin
- 0.00%
- Analyst target
- $19.83
- Volume
- 9.74k
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Lexington, MA, United States
- Employees
- 92
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.